12 Result(s)
within
Lizza E. L. Hendriks
-
Article
Open AccessSystematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer
Several population pharmacokinetic (popPK) studies have been reported that can guide the prediction of osimertinib plasma concentrations in individual patients. It is currently unclear which popPK model offers...
-
Article
Open AccessProactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer
Small-molecule inhibitors (SMIs) have revolutionised the treatment of non-small cell lung cancer (NSCLC). However, SMI-induced drug–drug interactions (DDIs) with frequently co-administered direct oral anticoag...
-
Article
Open AccessCorrection: Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer
-
Article
Open AccessTargeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer
Lung cancer is the most lethal cancer, and 85% of cases are classified as non-small cell lung cancer (NSCLC). Metabolic rewiring is a cancer hallmark that causes treatment resistance, and lacks insights into s...
-
Article
Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies
This review discusses the definitions, treatment modalities, management, future directions, and ongoing clinical trials of oligoprogressive disease in oncogene-driven and non-oncogene-driven NSCLC.
-
Article
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Therapeutic strategies harnessing the immune system to eliminate tumour cells have been successfully used for several cancer types, including in patients with advanced-stage non-small-cell lung cancer (NSCLC)....
-
Article
Open AccessA Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
Expensive novel anticancer drugs put a serious strain on healthcare budgets, and the associated drug expenses limit access to life-saving treatments worldwide.
-
Article
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized ...
-
Article
Open AccessGeneration of synthetic ground glass nodules using generative adversarial networks (GANs)
Data shortage is a common challenge in develo** computer-aided diagnosis systems. We developed a generative adversarial network (GAN) model to generate synthetic lung lesions mimicking ground glass nodules (...
-
Article
Open AccessCharacteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey study
For some patients with advanced cancer not knowing prognosis is essential. Yet, in an era of informed decision-making, the potential protective function of unawareness is easily overlooked. We aimed to investi...
-
Article
Open AccessAutomated detection and segmentation of non-small cell lung cancer computed tomography images
Detection and segmentation of abnormalities on medical images is highly important for patient management including diagnosis, radiotherapy, response evaluation, as well as for quantitative image research. We p...
-
Article
Open AccessStereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint ...
